TheEdgeResearch
Home / Stocks / SYMQY

SymBio Pharmaceuticals Limited (SYMQY)

OTC Healthcare Medical - Pharmaceuticals
$0.56 ▲ +0.00%
Market Cap
$26.4M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.53
52-Wk Range
0.5579-1.19
CEO
Fuminori Yoshida
Country
JP
Currency
USD

SymBio Pharmaceuticals Limited operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Tokyo, TY, JP. The stock last traded at $0.56, up 0.00% on the session, giving a market capitalisation of $26.4M. On trailing twelve-month figures it carries a trailing P/E of -0.71, a net margin of -532.9%. Its beta of 0.53 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.71
Price / Sales
3.46
Price / Book
-9.30
EV / EBITDA
-0.63
Gross margin
70.0%
Operating margin
-523.6%
Net margin
-532.9%
Return on equity
Debt / equity
-1.43
Current ratio
0.75
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
91
IPO date
2016-08-05
Headquarters
Tokyo, TY, JP
About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. It researches, develops, manufactures, and sells new drugs focusing on the areas of oncology, hematology, and autoimmune diseases. The company was founded by Fuminori Yoshida on March 25, 2005 and is headquartered in Tokyo, Japan.

Comparable companies

SymBio Pharmaceuticals Limited is most often compared with the following Healthcare names:

BIOGFEEOIFEOFBYGDNSFHRPMFINNPFKDEVFKIARFONPPFTIHE
More research on SYMQY
SYMQY technical analysis SYMQY TheEdge Score Compare against peers
Open full interactive analysis & DCF →